53 related articles for article (PubMed ID: 11279803)
21. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.
Crombet T; Torres O; Rodríguez V; Menéndez A; Stevenson A; Ramos M; Torres F; Figueredo R; Veitía I; Iznaga N; Pérez R; Lage A
Hybridoma; 2001 Apr; 20(2):131-6. PubMed ID: 11394532
[TBL] [Abstract][Full Text] [Related]
22. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
23. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
24. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
[TBL] [Abstract][Full Text] [Related]
25. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
27. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
Goldenberg DM; Juweid M; Dunn RM; Sharkey RM
J Nucl Med Technol; 1997 Mar; 25(1):18-23; quiz 34. PubMed ID: 9239599
[TBL] [Abstract][Full Text] [Related]
28. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
Peña Y; Perera A; Batista JF
MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
[TBL] [Abstract][Full Text] [Related]
29. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors.
Mach JP; Pèlegrin A; Buchegger F
Curr Opin Immunol; 1991 Oct; 3(5):685-93. PubMed ID: 1755986
[TBL] [Abstract][Full Text] [Related]
30. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Kashmiri SV; Iwahashi M; Tamura M; Padlan EA; Milenic DE; Schlom J
Crit Rev Oncol Hematol; 2001 Apr; 38(1):3-16. PubMed ID: 11255077
[TBL] [Abstract][Full Text] [Related]
31. Radioimmunoimaging and radioimmunotherapy: will these be routine procedures?
Bischof Delaloye A
Semin Nucl Med; 2000 Jul; 30(3):186-94. PubMed ID: 10928382
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunodetection of malignant solid tumours.
Kairemo KJ; Liewendahl K
Scand J Clin Lab Invest; 1994 Dec; 54(8):569-83. PubMed ID: 7709158
[TBL] [Abstract][Full Text] [Related]
33. Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy.
Ullén A; Ahlström KR; Heitala S; Nilsson B; Arlestig L; Stigbrand T
Acta Oncol; 1996; 35(3):281-5. PubMed ID: 8679257
[TBL] [Abstract][Full Text] [Related]
34. Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy.
Dijkers EC; de Vries EG; Kosterink JG; Brouwers AH; Lub-de Hooge MN
Curr Pharm Des; 2008; 14(31):3348-62. PubMed ID: 19075712
[TBL] [Abstract][Full Text] [Related]
35. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors.
Larson SM; Macapinlac HA; Scott AM; Divgi CR
Acta Oncol; 1993; 32(7-8):709-15. PubMed ID: 8305216
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies: application in radiopharmacy.
Ligiero TB; de Souza Albernaz M; de Carvalho SM; de Oliveira SM; Santos-Oliveira R
Curr Radiopharm; 2013 Dec; 6(4):231-48. PubMed ID: 24251731
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]